TABLE 3.
Behavioral, Clinical, and Other Characteristics of US Adults Receiving HIV Care Who Reported ART Initiation Stratified by ART Discontinuation and Current ART Use—MMP, 2009
| Total | ART Discontinuation | Current ART Use | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Sample, n |
Weighted, % |
95% CI for Weighted % |
Sample, n |
Weighted, % |
95% CI for Weighted, % |
Sample, n |
Weighted, % |
95% CI for Weighted % |
P* |
| Total | 3926 | 100.0 | 218 | 100.0 | 3708 | 100.0 | ||||
| Time since HIV diagnosis in years |
0.14 | |||||||||
| <5 | 791 | 20.6 | 18.8 to 22.3 | 36 | 16.1 | 11.9 to 20.3 | 755 | 20.8 | 19.0 to 22.7 | |
| 5–9 | 923 | 23.4 | 21.6 to 25.2 | 48 | 22.7 | 17.2 to 28.1 | 875 | 23.4 | 21.5 to 25.4 | |
| ≥10 | 2210 | 56.0 | 53.6 to 58.5 | 134 | 61.2 | 55.1 to 67.3 | 2076 | 55.7 | 53.3 to 58.2 | |
| Binge drinking | 655 | 16.0 | 14.6 to 17.4 | 42 | 19.5 | 14.5 to 24.5 | 613 | 15.8 | 14.3 to 17.2 | 0.14 |
| Injection drug use past 12 mo |
86 | 2.0 | 1.1 to 2.8 | 16 | 6.5 | 2.9 to 10.2 | 70 | 1.7 | 0.9 to 2.5 | <0.01 |
| Non–injection drug use past 12 mo† |
558 | 13.9 | 12.1 to 15.8 | 44 | 19.0 | 13.6 to 24.3 | 514 | 13.7 | 11.8 to 15.5 | 0.07 |
| Stimulant past 12 mo | 419 | 10.2 | 8.6 to 11.8 | 41 | 17.4 | 12.1 to 22.6 | 378 | 9.8 | 8.2 to 11.4 | <0.01 |
| Any major or other depression |
948 | 25.1 | 23.3 to 26.9 | 74 | 33.4 | 27.2 to 39.7 | 874 | 24.6 | 22.7 to 26.5 | 0.01 |
| Geometric mean CD4 count past 12 mo |
<0.01 | |||||||||
| 0–199 cells/mm3 | 530 | 13.0 | 11.5 to 14.5 | 32 | 15.3 | 9.7 to 20.8 | 498 | 12.9 | 11.4 to 14.4 | |
| 200–499 cells/mm3 | 1642 | 43.3 | 41.6 to 45.1 | 90 | 43.5 | 36.9 to 50.1 | 1552 | 43.3 | 41.5 to 45.1 | |
| ≥500 cells/mm3 | 1624 | 43.7 | 41.7 to 45.6 | 81 | 41.2 | 33.2 to 49.3 | 1543 | 43.8 | 41.8 to 45.8 | |
| Nadir CD4 | <0.01 | |||||||||
| 0–199 cells/mm3 | 1977 | 49.2 | 46.5 to 51.8 | 67 | 30.0 | 21.1 to 39.0 | 1910 | 50.3 | 47.8 to 52.8 | |
| 200–349 cells/mm3 | 1052 | 27.2 | 25.6 to 28.9 | 62 | 28.0 | 22.3 to 33.8 | 990 | 27.2 | 25.6 to 28.8 | |
| 350–499 cells/mm3 | 476 | 12.8 | 11.6 to 14.0 | 39 | 16.9 | 10.9 to 22.9 | 437 | 12.6 | 11.3 to 13.8 | |
| ≥500 cells/mm3 | 393 | 10.8 | 8.8 to 12.8 | 49 | 25.1 | 16.5 to 33.6 | 344 | 10.0 | 8.1 to 11.8 | |
| Most recent viral load‡ | <0.01 | |||||||||
| Undetectable | 2964 | 79.4 | 76.8 to 82.0 | 32 | 17.1 | 12.2 to 21.9 | 2932 | 82.8 | 80.3 to 85.3 | |
| Detectable | 778 | 20.6 | 18.0 to 23.2 | 163 | 82.9 | 78.1 to 87.8 | 615 | 17.2 | 14.7 to 19.7 | |
| Unmet need for supportive services, past 12 mo§ |
1171 | 30.6 | 28.6 to 32.6 | 109 | 48.9 | 41.9 to 55.9 | 1062 | 29.5 | 27.6 to 31.4 | <0.01 |
| Inadequate health literacy | 1441 | 36.5 | 33.7 to 39.3 | 75 | 32.3 | 25.9 to 38.7 | 1366 | 36.8 | 33.9 to 39.6 | 0.23 |
| No care past 3 mo | 761 | 19.8 | 17.5 to 22.2 | 55 | 27.1 | 20.1 to 34.2 | 706 | 19.4 | 17.0 to 21.8 | 0.04 |
*
Rao–Scott χ2 for ART discontinuation versus current ART use.
†
Excludes patients who reported using marijuana only in past 12 months.
‡
Most recent viral load from medical chart abstraction. Undetectable defined as result of “undetectable” or less than 400 copies per milliliter.
§
Adherence support, food/meals, ADAP, public benefits, transportation, mental health care, substance abuse, and HIV case management.
CI, confidence interval.